Project Details
Description
The primary purpose of this study is to compare the effect of mitapivat versus placebo on anemia in participants with alpha- or beta-non-transfusion dependent thalassemia (NTDT).
Layman's description
The mitapivat group will include approximately 114 participants. The placebo group will include approximately 57 participants.
| Acronym | ENERGIZE |
|---|---|
| Status | Active |
| Effective start/end date | 8/11/21 → 31/12/28 |
Collaborative partners
- Agios Pharmaceuticals, Inc. (lead)
- Burjeel Medical City
- Dubai Thalassemia Center
- Abu Dhabi Health Services Company
Keywords
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Anemia
- Hematologic Diseases
- Hemoglobinopathies
- Genetic Diseases, Inborn
- Thalassemia
- beta-Thalassemia
- alpha-Thalassemia
- Enzyme Activators
- Molecular Mechanisms of Pharmacological Action
- Mitapivat
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.